New nasal spray could tame stage fright in social anxiety
NCT ID NCT06358651
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether a nasal spray called fasedienol can quickly reduce anxiety during a public speaking challenge in adults with social anxiety disorder. About 238 participants will receive either the spray or a placebo before speaking. The study also looks at long-term safety for up to 12 months of use as needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fasedienol nasal spray
What this could lead to
If successful, this could offer a fast-acting, on-demand treatment for anxiety triggered by public speaking in people with social anxiety disorder.
What could go wrong
This is a Phase 3 trial, but results are not yet known. The effect may be modest, and the spray is only for acute episodes, not a long-term solution. Side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOCIAL ANXIETY DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vistagen Clinical Site
Phoenix, Arizona, 85012, United States
-
Vistagen Clinical Site
Fayetteville, Arkansas, 72703, United States
-
Vistagen Clinical Site
Little Rock, Arkansas, 72211, United States
-
Vistagen Clinical Site
Lafayette, California, 94549, United States
-
Vistagen Clinical Site
Oceanside, California, 92056, United States
-
Vistagen Clinical Site
Sherman Oaks, California, 91403, United States
-
Vistagen Clinical Site
Denver, Colorado, 80209, United States
-
Vistagen Clinical Site
Cromwell, Connecticut, 06416, United States
-
Vistagen Clinical Site
Jacksonville, Florida, 32256, United States
-
Vistagen Clinical Site
Lakeland, Florida, 33803, United States
-
Vistagen Clinical Site
Orlando, Florida, 32801, United States
-
Vistagen Clinical Site
West Palm Beach, Florida, 33407, United States
-
Vistagen Clinical Site
Chicago, Illinois, 60612, United States
-
Vistagen Clinical Site
Overland Park, Kansas, 66210, United States
-
Vistagen Clinical Site
Baltimore, Maryland, 21208, United States
-
Vistagen Clinical Site
Boston, Massachusetts, 02131, United States
-
Vistagen Clinical Site
Saint Charles, Missouri, 63304, United States
-
Vistagen Clinical Site
Las Vegas, Nevada, 89119, United States
-
Vistagen Clinical Site
New York, New York, 10128, United States
-
Vistagen Clinical Site
Media, Pennsylvania, 19063, United States
-
Vistagen Clinical Site
Memphis, Tennessee, 38119, United States
-
Vistagen Clinical Site
Fort Worth, Texas, 76104, United States
-
Vistagen Clinical Site
Draper, Utah, 84020, United States
-
Vistagen Clinical Site
Everett, Washington, 98201, United States